<i>N</i>
-hydroxy-substituted 2-aryl acetamide analogs: A novel class of HIV-1 integrase inhibitors
作者:Utsab Debnath、Prachi Kumar、Aakanksha Agarwal、Ajay Kesharwani、Satish K. Gupta、Seturam B. Katti
DOI:10.1111/cbdd.12974
日期:2017.10
as a newclass of HIV-1integraseinhibitors. Based on the molecular requirements of the binding pocket of catalytic active site, two molecules (compounds 2 and 4b) were designed as fragments. These were further synthesized and biologically evaluated. In vitro potency along with docking studies highlighted compound 4b as an active fragment which was further used to synthesize new leads as HIV-1 integrase
Copper(I)‐Catalyzed Decarboxylative <i>N</i>‐Phosphorylation: Modular Preparation of <i>N</i>‐Acyl Iminophosphoranes Using Dioxazolones and Phosphines
作者:Jinhwan Park、Anattil Unnikrishnan Krishnapriya、Yeongmi Park、Minsuk Kim、Tyler W. Reidl、Rositha Kuniyil、Jongwoo Son
DOI:10.1002/adsc.202300693
日期:2023.12.19
Dioxazolones and phosphines have been used to access N-acyl iminophosphoranes in copper(I) catalysis under simple thermal conditions. The synthetic utility of this protocol is demonstrated by a broad range of substrates with an excellent atom-economy. The optimization process showed that copper demonstrated as catalytic amount toward the targeted transformation. Functionalization studies of N-acyl
2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS
申请人:Merck & Co., Inc.
公开号:EP1366012A2
公开(公告)日:2003-12-03
[EN] 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS<br/>[FR] ACIDES 2-ARYLOXY-2-ARYLALCANOÏQUES UTILISÉS POUR LE TRAITEMENT DU DIABÈTES ET DES TROUBLES LIPIDIQUES
申请人:MERCK & CO INC
公开号:WO2002064094A2
公开(公告)日:2002-08-22
A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.